Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.

ABSTRACT:

Background

Eosinophilic asthma and nasal polyposis are hallmarks of aspirin-exacerbated respiratory disease (AERD), and IL-5 inhibition has been shown to provide therapeutic benefit. However, IL-5Rα is expressed on many cells in addition to eosinophils, and the mechanisms by which IL-5 inhibition leads to clinical benefit in eosinophilic asthma and nasal polyposis are unlikely to be due exclusively to antieosinophil effects.

Objective

We sought to identify the mechanisms by which anti-IL-5 treatment with mepolizumab improves respiratory inflammation in AERD.

Methods

The clinical characteristics, circulating granulocytes, nasal scraping transcripts, eosinophilic cationic protein, tryptase, and antibody levels, and urinary and nasal eicosanoid levels were measured for 1

SUBMITTER: Buchheit KM 

PROVIDER: S-EPMC9096876 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature